Utility of next generation sequencing in clinical primary immunodeficiencies.
DOI: 10.1007/s11882-014-0468-y; PMCID: PMC4582650
Primary immunodeficiencies (PIDs) are a group of genetically heterogeneous disorders that present with very similar symptoms, complicating definitive diagnosis. More than 240 genes have hitherto been associated with PIDs, of which more than 30 have been identified in the last 3 years. Next generation sequencing (NGS) of genomes or exomes of informative families has played a central role in the discovery of novel PID genes. Furthermore, NGS has the potential to transform clinical molecular testing for established PIDs, allowing all PID differential diagnoses to be tested at once, leading to increased diagnostic yield, while decreasing both the time and cost of obtaining a molecular diagnosis. Given that treatment of PID varies by disease gene, early achievement of a molecular diagnosis is likely to enhance treatment decisions and improve patient outcomes.
Current allergy and asthma reports
Diagnosis, Differential; Exome; Genetic Markers; Genetic Testing; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Immunologic Deficiency Syndromes; Polymorphism, Single Nucleotide; Sequence Analysis, DNA
Whole genome sequencing, Whole exome sequencing, Primary immunodeficiency, Next generation sequencing, Single nucleotide variation, Single nucleotide polymorphism
Raje, N., Soden, S., Swanson, D., Ciaccio, C. E., Kingsmore, S. F., Dinwiddie, D. Utility of next generation sequencing in clinical primary immunodeficiencies. Current allergy and asthma reports 14, 468-468 (2014).